Bausch

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance

Retrieved on: 
Wednesday, February 21, 2024

For the fourth quarter of 2023, the change was primarily due to higher interest expense and the decrease in operating results noted above.

Key Points: 
  • For the fourth quarter of 2023, the change was primarily due to higher interest expense and the decrease in operating results noted above.
  • Adjusted EPS attributable to Bausch + Lomb Corporation (non-GAAP)1 for the fourth quarter of 2023 was $0.24, as compared to $0.23 for the fourth quarter of 2022.
  • Adjusted EPS attributable to Bausch + Lomb Corporation (non-GAAP)1 for the full year of 2023 was $0.73, as compared to $1.07 for the full year of 2022.
  • Bausch + Lomb provided guidance for the full year of 2024, as follows.

Dr. Kent Wellish Successfully Implants First Bausch + Lomb Toric Aspire "Range of Vision" IOL in Las Vegas

Retrieved on: 
Thursday, March 7, 2024

PHOENIX, March 7, 2024 /PRNewswire-PRWeb/ -- Dr. Kent Wellish of Wellish Vision Institute, an affiliate of American Vision Partners, has achieved a significant milestone in the field of ophthalmology by successfully implanting the first Bausch + Lomb Toric Aspire "Range of Vision" intraocular lens (IOL) in Las Vegas. This innovative lens offers patients with cataracts the potential for improved vision at various distances.

Key Points: 
  • Dr. Kent Wellish of Wellish Vision Institute, an affiliate of American Vision Partners, has achieved a significant milestone in the field of ophthalmology by successfully implanting the first Bausch + Lomb Toric Aspire "Range of Vision" intraocular lens (IOL) in Las Vegas.
  • PHOENIX, March 7, 2024 /PRNewswire-PRWeb/ -- Dr. Kent Wellish of Wellish Vision Institute, an affiliate of American Vision Partners, has achieved a significant milestone in the field of ophthalmology by successfully implanting the first Bausch + Lomb Toric Aspire "Range of Vision" intraocular lens (IOL) in Las Vegas.
  • The Bausch + Lomb Toric Aspire "Range of Vision" IOL, recently launched as Envista Aspire is designed to provide an extended range of vision, including intermediate vision, reducing the need for glasses for activities such as reading, computer use, and driving.
  • Visit https://ir.bausch.com/ for more information about the Bausch + Lomb Toric Aspire "Range of Vision" IOL.

Selkirk Pharma Announces New APS Qualified Facility with Advanced Fill/Finish Capacity in Spokane, WA

Retrieved on: 
Thursday, February 15, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240215019715/en/
    Selkirk Pharma's state-of-the-art APS qualified facility, purpose-built for contract manufacturing with advanced fill/finish capabilities and unidirectional flow technology.
  • The new US based facility will be crucial in alleviating growing demands and capacity constraints within the fill/finish industry.
  • “The completion of our facility's aseptic process simulation qualification is a milestone achievement for the Selkirk team,” said John Bertagnolli, Vice President of Operations at Selkirk Pharma.
  • To learn more about Selkirk Pharma’s available capacity, capabilities, and commitment to quality, please contact Selkirk Pharma via www.selkirkpharma.com or email [email protected] .

Ace Vision Group Names Val Kolesnitchenko, MD as Chief Scientific Officer

Retrieved on: 
Tuesday, February 13, 2024

BOSTON, Feb. 13, 2024 /PRNewswire/ -- Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye and presbyopia, announced that it has named Val Kolesnitchenko, MD, as Chief Scientific Officer.

Key Points: 
  • BOSTON, Feb. 13, 2024 /PRNewswire/ -- Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye and presbyopia, announced that it has named Val Kolesnitchenko, MD , as Chief Scientific Officer.
  • "Dr. Kolesnitchenko has a strong foundation in both surgical and therapeutic ophthalmology, as well as highly developed interpersonal skills and industry relationships," said Dr. AnnMarie Hipsley, CEO of Ace Vision Group.
  • Val's assignment to the company as Chief Scientific Officer comes at a very timely period in the company's preparations for its medical device regulatory submissions.
  • "I look forward to working with Ace Vision Group on this revolutionary approach to presbyopia," said Dr. Kolesnitchenko.

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2023 Financial Results on February 21

Retrieved on: 
Monday, February 5, 2024

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2023 financial results on Wednesday, Feb. 21, 2024.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2023 financial results on Wednesday, Feb. 21, 2024.
  • Bausch + Lomb will host a conference call and live webcast at 8 a.m.
  • ET to discuss the results and provide a business update.
  • All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.

Contact Lens Solutions Market size to grow by USD 540.94 million from 2023 to 2028, Increased preference for contact lenses over spectacles to boost the market- Technavio

Retrieved on: 
Tuesday, January 9, 2024

NEW YORK, Jan. 8, 2024 /PRNewswire/ -- The contact lens solutions market is estimated to grow by USD 540.94 million from 2023 to 2028, according to Technavio.

Key Points: 
  • NEW YORK, Jan. 8, 2024 /PRNewswire/ -- The contact lens solutions market is estimated to grow by USD 540.94 million from 2023 to 2028, according to Technavio.
  • The North American contact lens solutions market has experienced consistent growth, attributed to widespread product usage, availability, and the presence of established suppliers.
  • The Contact Lens Solutions Market showcases steady growth due to increased demand for corrective vision aids like Novartis and Bausch & Lomb's offerings.
  • The contact lenses market size is estimated to grow at a CAGR of 5.58% between 2022 and 2027.

Bausch + Lomb to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 3, 2024

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat with investors at the 42nd Annual J.P. Morgan Healthcare Conference on Jan. 8, 2024, at 11:15 a.m. PT (2:15 p.m.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat with investors at the 42nd Annual J.P. Morgan Healthcare Conference on Jan. 8, 2024, at 11:15 a.m. PT (2:15 p.m.
  • ET).
  • Other company executives, including Chief Financial Officer Sam Eldessouky and Global Pharmaceuticals and International Consumer President Andrew Stewart, will also participate in the conference.
  • A live webcast and audio archive of the event will be available on the Investor Relations page of the Bausch + Lomb website: https://ir.bausch.com/investors/events-presentations .

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

Retrieved on: 
Wednesday, December 20, 2023

CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA ) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, has appointed Sanjeev Luther as President and Chief Executive Officer and a member of the company's Board of Directors, effective January 1, 2024.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA ) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, has appointed Sanjeev Luther as President and Chief Executive Officer and a member of the company's Board of Directors, effective January 1, 2024.
  • Mr. Luther will replace Matt Angel, Ph.D., the current President and Chief Executive Officer.
  • Sanjeev has an impressive track record in leadership, strategic planning, and business development across various global organizations in the pharmaceutical and healthcare sectors.
  • At Cornerstone, he also held the roles of Chief Operations Officer and Chief Business Officer.

Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 13, 2023

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage, topical ophthalmic company leveraging its Optejet® dispensing technology for both internally developed and acquired programs as well as out-licensing for additional indications, today announced its financial and operating results for the third quarter ended September 30, 2023.

Key Points: 
  • Advanced its Gen-2 Optejet device and anticipates shipping to MicroPine partners Bausch and Lomb and Arctic Vision by year-end 2023.
  • Research and development expenses totaled approximately $3.6 million for the third quarter of 2023 as compared to $3.9 million for the third quarter of 2022.
  • For the third quarter of 2023, general and administrative expenses were approximately $2.9 million, compared to $3.4 million for the third quarter of 2022.
  • Total operating expenses for the third quarter of 2023 were approximately $6.5 million compared to $7.2 million for the third quarter of 2022.

Bausch + Lomb Reports More Than 76 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

Retrieved on: 
Wednesday, November 15, 2023

Contact lenses, eye care and lens care materials aren’t typically processed in standard recycling facilities due to the small size and the type of plastic used to manufacture them.

Key Points: 
  • Contact lenses, eye care and lens care materials aren’t typically processed in standard recycling facilities due to the small size and the type of plastic used to manufacture them.
  • “My patients appreciate being able to recycle their used eye health materials through the Bausch + Lomb recycling programs in an environmentally responsible way,” said Jennifer Tsai, O.D., LINE OF SIGHT, New York.
  • In addition to the United States, Bausch + Lomb has a similar contact lens recycling program in Canada called Every Contact Counts.
  • To learn more about the Biotrue Eye Care Recycling program, visit https://www.biotrue.com/terracycle/ .